Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00748046 · ClinicalTrials.gov registry record · Phase 1
Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00748046 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 10 participants.
The verdict
NCT00748046, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of three intravenous escalating dose levels of Xofigo (Alpharadin).
Interventions
- DRUG Radium-223 chloride (BAY88-8223)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00748046
The ClinicalTrials.gov registry entry for NCT00748046 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radium-223 chloride (BAY88-8223) is the first listed.
NCT00748046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00748046 about?
NCT00748046 is a clinical study titled "Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton". The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of three intravenous escalating dose levels of Xofigo (Alpharadin).
What is the current status of trial NCT00748046?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2008-08. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00748046?
The interventions under investigation include: Radium-223 chloride (BAY88-8223) (DRUG).
Who is sponsoring clinical trial NCT00748046?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.